CA2295029A1 - Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus - Google Patents

Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus Download PDF

Info

Publication number
CA2295029A1
CA2295029A1 CA002295029A CA2295029A CA2295029A1 CA 2295029 A1 CA2295029 A1 CA 2295029A1 CA 002295029 A CA002295029 A CA 002295029A CA 2295029 A CA2295029 A CA 2295029A CA 2295029 A1 CA2295029 A1 CA 2295029A1
Authority
CA
Canada
Prior art keywords
pulses
electrode
tissue
volts
electrotransfer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295029A
Other languages
English (en)
Inventor
Daniel Scherman
Bertrand Schwartz
Lluis Mir
Michel Bureau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Gustave Roussy (IGR)
Aventis Pharma SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9708233A external-priority patent/FR2765242B1/fr
Priority claimed from FR9708232A external-priority patent/FR2765241B1/fr
Application filed by Individual filed Critical Individual
Publication of CA2295029A1 publication Critical patent/CA2295029A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body

Abstract

Cette invention concerne des systèmes et des dispositifs permettant d'améliorer de manière significative le transfert in vivo de vecteurs d'acides nucléiques dans des cellules, en particulier des cellules musculaires et des cellules tumorales et ce, grâce à des champs électriques faibles destinés à accroître l'efficacité de tels transferts. Les dispositifs selon l'invention sont conçus pour assurer un gradient de tension optimal destiné à améliorer la migration de vecteurs d'acides nucléiques dans des cellules et ce, sans abîmer les cellules ou les tissus. De tels dispositifs sont caractérisés par des agencements uniques d'électrodes et par des limites de puissance uniques définies par des réglages sur des valeurs de tension maximales.
CA002295029A 1997-06-30 1998-06-30 Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus Abandoned CA2295029A1 (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
FR9708233A FR2765242B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
FR97/08233 1997-06-30
FR97/08232 1997-06-30
FR9708232A FR2765241B1 (fr) 1997-06-30 1997-06-30 Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede
US6748897P 1997-12-01 1997-12-01
US6748797P 1997-12-01 1997-12-01
US60/067,488 1997-12-01
US60/067,487 1997-12-01
US8385898P 1998-05-01 1998-05-01
US60/083,858 1998-05-01
PCT/EP1998/003976 WO1999001175A1 (fr) 1997-06-30 1998-06-30 Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus

Publications (1)

Publication Number Publication Date
CA2295029A1 true CA2295029A1 (fr) 1999-01-14

Family

ID=27515625

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295029A Abandoned CA2295029A1 (fr) 1997-06-30 1998-06-30 Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus

Country Status (11)

Country Link
EP (1) EP0993318A1 (fr)
JP (1) JP2002515816A (fr)
KR (1) KR20010014298A (fr)
CN (1) CN1261812A (fr)
AU (1) AU8730798A (fr)
BR (1) BR9810500A (fr)
CA (1) CA2295029A1 (fr)
IL (1) IL133709A0 (fr)
NO (1) NO996540L (fr)
PL (1) PL337617A1 (fr)
WO (1) WO1999001175A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2753379B1 (fr) 1996-09-13 1998-10-30 Rhone Poulenc Rorer Sa Methode de traitement de la sclerose laterale amyotrophique
US6261281B1 (en) * 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
CA2361601A1 (fr) * 1999-02-08 2000-08-10 Cheryl Goldbeck Augmentation electriquement induite de l'immunite et de l'efficacite de vaccins d'adn in vivo
EP1276500B1 (fr) 2000-03-13 2011-06-08 Cornell Research Foundation, Inc. Inhibition de la migration des leucocytes et d'une inflammation par perturbation de cd99/hec2
EP2264072A1 (fr) 2000-04-13 2010-12-22 The Rockefeller University Amélioration de la réponse cytotoxique à médiation d'anticorps.
JP2004532654A (ja) 2000-05-22 2004-10-28 マーク・アンド・カンパニー・インコーポレイテッド 薬剤投与システム性能評価システム及び方法
US7118756B2 (en) 2000-12-28 2006-10-10 Wyeth Recombinant protective protein from Streptococcus pneumoniae
DE60234475D1 (de) 2001-03-02 2009-12-31 Univ Rockefeller Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
US20020198567A1 (en) * 2001-06-07 2002-12-26 Yona Keisari Electro-endocytotic therapy as a treatment modality of cancer
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2003230601A1 (en) 2002-03-07 2003-09-22 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Clinical syringe with electrical stimulation aspects
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP1759714A1 (fr) * 2005-09-02 2007-03-07 Bioalliance Pharma Electrotransfert d'acides nucléiques dans des cellules tissulaires
CN101321555B (zh) * 2005-10-03 2020-12-08 诺沃库勒有限责任公司 优化电场特征以增加电场在增殖细胞上的效果
JP4961137B2 (ja) * 2005-12-14 2012-06-27 久光製薬株式会社 イオントフォレーシス用デバイス
PL2068922T3 (pl) 2006-10-19 2012-11-30 Csl Ltd Przeciwciała anty-IL-13R alfa1 i ich zastosowania
DK2068921T3 (da) 2006-10-19 2014-09-15 Csl Ltd Antistof-antagonister med høj affinitet af interleukin-13-receptor alpha 1
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US8246176B2 (en) 2007-03-06 2012-08-21 Sanyo Electric Co., Ltd. Projection display device having an operation section for displacing a lens
US8093043B2 (en) 2008-06-04 2012-01-10 New York University β-TrCP1, β-TrCP2 and RSK1 or RSK2 inhibitors and methods for sensitizing target cells to apoptosis
EP2310500B1 (fr) * 2008-07-18 2015-03-11 Maxcyte, Inc. Procédés d'optimisation de l'électroporation
RU2478396C2 (ru) 2008-11-05 2013-04-10 ВАЙЕТ ЭлЭлСи МНОГОКОМПОНЕНТНАЯ ИММУНОГЕННАЯ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ЗАБОЛЕВАНИЯ, ВЫЗВАННОГО β-ГЕМОЛИТИЧЕСКИМИ СТРЕПТОКОККАМИ (БГС)
ES2639035T3 (es) 2010-08-23 2017-10-25 Wyeth Llc Formulaciones estables de antígenos rLP2086 de Neisseria meningitidis
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
AU2013229063B2 (en) 2012-03-09 2016-10-06 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
WO2014107739A1 (fr) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Anticorps dirigés contre pcsk9
EP2964665B1 (fr) 2013-03-08 2018-08-01 Pfizer Inc Polypeptides immunogènes de fusion
KR20210002757A (ko) 2013-09-08 2021-01-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
RU2723045C2 (ru) 2015-02-19 2020-06-08 Пфайзер Инк. Композиции neisseria meningitidis и способы их получения
IL303108B1 (en) 2017-01-31 2024-03-01 Pfizer NEISSERIA MENINGITIDIS preparations and methods therefor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
US5641680A (en) * 1994-11-14 1997-06-24 Zhao; Xi Gene transfer apparatus and method for using the same
WO1997007826A1 (fr) * 1995-08-29 1997-03-06 Cbr Laboratories, Inc. Electroporation in vivo de cellules

Also Published As

Publication number Publication date
CN1261812A (zh) 2000-08-02
JP2002515816A (ja) 2002-05-28
NO996540L (no) 2000-02-03
AU8730798A (en) 1999-01-25
IL133709A0 (en) 2001-04-30
EP0993318A1 (fr) 2000-04-19
PL337617A1 (en) 2000-08-28
BR9810500A (pt) 2000-09-05
NO996540D0 (no) 1999-12-29
KR20010014298A (ko) 2001-02-26
WO1999001175A1 (fr) 1999-01-14

Similar Documents

Publication Publication Date Title
CA2295029A1 (fr) Dispositif permettant un transfert in vivo optimise de vecteurs d'acides nucleiques dans des tissus
US6939862B2 (en) Method for transferring nucleic acid into striated muscles
JP4664450B2 (ja) 多細胞化真核生物細胞に核酸を導入する改良法およびその組合せ
US7054685B2 (en) Method and apparatus for reducing electroporation-mediated muscle reaction and pain response
Vicat et al. Brief report: muscle transfection by electroporation with high-voltage and short-pulse currents provides high-level and long-lasting gene expression
Heller et al. Electrically mediated delivery of plasmid DNA to the skin, using a multielectrode array
EP1171189B1 (fr) Appareil permettant de reduire la reaction musculaire induite par electroporation et la reponse douloureuse
Prausnitz et al. Methods for in vivo tissue electroporation using surface electrodes
MXPA99011527A (en) Device for optimized electrotransfer of nucleic acid vectors to tissues in vivo
CZ475699A3 (cs) Systém a zařízení pro in vivo přenos nukleových kyselin do tkání
MXPA99011444A (es) Metodo mejorado de transferencia de acidos nucleicos enmusculo estraido y combinaciones que permienn el uso del procedimiento
JP2005524389A (ja) 宿主組織内への核酸分子の電気的遺伝子導入の増強
AU4439102A (en) Improved method for transferring nucleic acid into the striped muscle and combination therefor
AU4576202A (en) Improvement in the transfer of nucleic acid into the cells of pluricellular eukaryotic organisms and combination allowing the method to be carried out

Legal Events

Date Code Title Description
FZDE Discontinued